Applied physiologically-based pharmacokinetic modeling to assess uridine diphosphate-glucuronosyltransferase-mediated drug-drug interactions for Vericiguat.
Journal
CPT: pharmacometrics & systems pharmacology
ISSN: 2163-8306
Titre abrégé: CPT Pharmacometrics Syst Pharmacol
Pays: United States
ID NLM: 101580011
Informations de publication
Date de publication:
04 Oct 2023
04 Oct 2023
Historique:
revised:
21
09
2023
received:
13
06
2023
accepted:
25
09
2023
pubmed:
5
10
2023
medline:
5
10
2023
entrez:
5
10
2023
Statut:
aheadofprint
Résumé
Vericiguat (Verquvo; US: Merck, other countries: Bayer) is a novel drug for the treatment of chronic heart failure. Preclinical studies have demonstrated that the primary route of metabolism for vericiguat is glucuronidation, mainly catalyzed by uridine diphosphate-glucuronosyltransferase (UGT)1A9 and to a lesser extent UGT1A1. Whereas a drug-drug interaction (DDI) study of the UGT1A9 inhibitor mefenamic acid showed a 20% exposure increase, the effect of UGT1A1 inhibitors has not been assessed clinically. This modeling study describes a physiologically-based pharmacokinetic (PBPK) approach to complement the clinical DDI liability assessment and support prescription labeling. A PBPK model of vericiguat was developed based on in vitro and clinical data, verified against data from the mefenamic acid DDI study, and applied to assess the UGT1A1 DDI liability by running an in silico DDI study with the UGT1A1 inhibitor atazanavir. A minor effect with an area under the plasma concentration-time curve (AUC) ratio of 1.12 and a peak plasma concentration ratio of 1.04 was predicted, which indicates that there is no clinically relevant DDI interaction anticipated. Additionally, the effect of potential genetic polymorphisms of UGT1A1 and UGT1A9 was evaluated, which showed that an average modest increase of up to 1.7-fold in AUC may be expected in the case of concomitantly reduced UGT1A1 and UGT1A9 activity for subpopulations expressing non-wild-type variants for both isoforms. This study is a first cornerstone to qualify the PK-Sim platform for use of UGT-mediated DDI predictions, including PBPK models of perpetrators, such as mefenamic acid and atazanavir, and sensitive UGT substrates, such as dapagliflozin and raltegravir.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 The Authors. CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
Références
Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020;382:1883-1893.
Food and Drug Administration. VERQUVO prescribing information. 2021. Accessed February 8, 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214377s000lbl.pdf
Boettcher M, Gerisch M, Lobmeyer M, et al. Metabolism and pharmacokinetic drug-drug interaction profile of vericiguat, a soluble guanylate cyclase stimulator: results from preclinical and phase I healthy volunteer studies. Clin Pharmacokinet. 2020;59:1407-1418.
Boettcher M, Loewen S, Gerrits M, Becker C. Pharmacodynamic and pharmacokinetic interaction profile of vericiguat: results from three randomized phase I studies in healthy volunteers. Clin Pharmacokinet. 2021;60:337-351.
Food and Drug Administration. In vitro drug interaction studies - cytochrome P450 enzyme- and transporter-mediated drug interactions guidance for industry. 2020 Accessed July 4, 2022. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/vitro-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions
European Medicines Agency. Guideline on the investigation of drug interactions - Revision 1. 2015 Accessed July 4, 2022. https://www.ema.europa.eu/en/investigation-drug-interactions
Frechen S, Rostami-Hodjegan A. Quality assurance of PBPK modeling platforms and guidance on building, evaluating, verifying and applying PBPK models prudently under the umbrella of qualification: why, when, what, how and by whom? Pharm Res. 2022;39:1733-1748.
European Medicines Agency. Physiologically based pharmacokinetic analyses-format and content guidance for industry. 2022 Accessed July 1, 2022. https://www.ema.europa.eu/en/reporting-physiologically-based-pharmacokinetic-pbpk-modelling-simulation
Grimstein M, Yang Y, Zhang X, et al. Physiologically based pharmacokinetic modeling in regulatory science: an update from the U.S. Food and Drug Administration's Office of Clinical Pharmacology. J Pharm Sci. 2019;108:21-25.
Luzon E, Blake K, Cole S, Nordmark A, Versantvoort C, Berglund EG. Physiologically based pharmacokinetic modeling in regulatory decision-making at the European medicines agency. Clin Pharmacol Ther. 2017;102:98-105.
Zhang X, Yang Y, Grimstein M, et al. Application of PBPK modeling and simulation for regulatory decision making and its impact on US prescribing information: an update on the 2018-2019 submissions to the US FDA's office of clinical pharmacology. J Clin Pharmacol. 2020;60(Suppl 1):S160-S178.
Kilford PJ, Chen KF, Crewe K, et al. Prediction of CYP-mediated DDIs involving inhibition: approaches to address the requirements for system qualification of the Simcyp simulator. CPT Pharmacometrics Syst Pharmacol. 2022;11:822-832.
Frechen S, Solodenko J, Wendl T, et al. A generic framework for the physiologically-based pharmacokinetic platform qualification of PK-Sim and its application to predicting cytochrome P450 3A4-mediated drug-drug interactions. CPT Pharmacometrics Syst Pharmacol. 2021;10:633-644.
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Drug interaction studies M12. 2022 Accessed December 7, 2022. https://database.ich.org/sites/default/files/M12_Step1_draft_Guideline_2022_0524.pdf
Callegari E, Lin J, Tse S, Goosen TC, Sahasrabudhe V. Physiologically-based pharmacokinetic modeling of the drug-drug interaction of the UGT substrate ertugliflozin following co-administration with the UGT inhibitor mefenamic acid. CPT Pharmacometrics Syst Pharmacol. 2021;10:127-136.
Konishi K, Minematsu T, Nagasaka Y, Tabata K. Physiologically-based pharmacokinetic modeling for mirabegron: a multi-elimination pathway mediated by cytochrome P450 3A4, uridine 5′-diphosphate-glucuronosyltransferase 2B7, and butyrylcholinesterase. Xenobiotica. 2019;49:912-921.
Conner TM, Nikolian VC, Georgoff PE, et al. Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for valproic acid and divalproex. Eur J Pharm Sci. 2018;111:465-481.
Stingl JC, Bartels H, Viviani R, Lehmann ML, Brockmöller J. Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: a quantitative systematic review. Pharmacol Ther. 2014;141:92-116.
Shebley M, Sandhu P, Emami Riedmaier A, et al. Physiologically based pharmacokinetic model qualification and reporting procedures for regulatory submissions: a consortium perspective. Clin Pharmacol Ther. 2018;104:88-110.
Nishimura M, Yaguti H, Yoshitsugu H, Naito S, Satoh T. Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi. 2003;123:369-375.
Nishimura M, Naito S. Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. Drug Metab Pharmacokinet. 2005;20:452-477.
Nishimura M, Naito S. Tissue-specific mRNA expression profiles of human phase I metabolizing enzymes except for cytochrome P450 and phase II metabolizing enzymes. Drug Metab Pharmacokinet. 2006;21:357-374.
Ohtsuki S, Schaefer O, Kawakami H, et al. Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities. Drug Metab Dispos. 2012;40:83-92.
Tucker TG, Milne AM, Fournel-Gigleux S, Fenner KS, Coughtrie MW. Absolute immunoquantification of the expression of ABC transporters P-glycoprotein, breast cancer resistance protein and multidrug resistance-associated protein 2 in human liver and duodenum. Biochem Pharmacol. 2012;83:279-285.
Rodríguez-Antona C, Donato MT, Pareja E, Gómez-Lechón MJ, Castell JV. Cytochrome P-450 mRNA expression in human liver and its relationship with enzyme activity. Arch Biochem Biophys. 2001;393:308-315.
Open Systems Pharmacology. PK-SIM® and MOBI® for PBPK and quantitative systems pharmacology. Accessed July 4, 2022. https://www.open-systems-pharmacology.org/
Open Systems Pharmacology. Release of OSP qualification framework. Accessed December 18, 2020. https://github.com/Open-Systems-Pharmacology/QualificationPlan/releases
Kasichayanula S, Liu X, Griffen SC, Lacreta FP, Boulton DW. Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin. Diabetes Obes Metab. 2013;15:280-283.
Iwamoto M, Wenning LA, Mistry GC, et al. Atazanavir modestly increases plasma levels of raltegravir in healthy subjects. Clin Infect Dis. 2008;47:137-140.
Krishna R, East L, Larson P, et al. Atazanavir increases the plasma concentrations of 1200 mg raltegravir dose. Biopharm Drug Dispos. 2016;37:533-541.
Neely M, Decosterd L, Fayet A, et al. Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers. Antimicrob Agents Chemother. 2010;54:4619-4625.
Zhu L, Butterton J, Persson A, et al. Pharmacokinetics and safety of twice-daily atazanavir 300 mg and raltegravir 400 mg in healthy individuals. Antivir Ther. 2010;15:1107-1114.
Guest EJ, Aarons L, Houston JB, Rostami-Hodjegan A, Galetin A. Critique of the two-fold measure of prediction success for ratios: application for the assessment of drug-drug interactions. Drug Metab Dispos. 2011;39:170-173.
Frechen S. Building and evaluation of a PBPK model for mefenamic acid in adults. 2020 Accessed July 4, 2022. https://github.com/Open-Systems-Pharmacology/Mefenamic-acid-Model/releases/tag/v1.0
Frechen S. Building and evaluation of a PBPK Model for dapagliflozin in adults. 2020 Accessed July 4, 2022. https://github.com/Open-Systems-Pharmacology/Dapagliflozin-Model/releases/tag/v1.0
Dallmann A. Building and evaluation of a PBPK model for atazanavir in healthy adults. 2020 Accessed July 4, 2022. https://github.com/Open-Systems-Pharmacology/Atazanavir-Model/releases/tag/v1.0
Ince I. Building and evaluation of a PBPK model for raltegravir in adults. 2020 Accessed July 4, 2022. https://github.com/Open-Systems-Pharmacology/Raltegravir-Model/releases/tag/v1.0
Boettcher M, Thomas D, Mueck W, et al. Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects. Eur J Clin Pharmacol. 2021;77:527-537.
Blaut M. Ecology and physiology of the intestinal tract. Curr Top Microbiol Immunol. 2013;358:247-272.
Molly K, Vande Woestyne M, Verstraete W. Development of a 5-step multi-chamber reactor as a simulation of the human intestinal microbial ecosystem. Appl Microbiol Biotechnol. 1993;39:254-258.
Possemiers S, Verthé K, Uyttendaele S, Verstraete W. PCR-DGGE-based quantification of stability of the microbial community in a simulator of the human intestinal microbial ecosystem. FEMS Microbiol Ecol. 2004;49:495-507.
Sakamoto H, Yokota H, Kibe R, Sayama Y, Yuasa A. Excretion of bisphenol A-glucuronide into the small intestine and deconjugation in the cecum of the rat. Biochim Biophys Acta. 2002;1573:171-176.
Kuepfer L, Niederalt C, Wendl T, et al. Applied concepts in PBPK modeling: how to build a PBPK/PD model. CPT Pharmacometrics Syst Pharmacol. 2016;5:516-531.
Wenning LA, Petry AS, Kost JT, et al. Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms. Clin Pharmacol Ther. 2009;85:623-627.
Satoh T, Ura T, Yamada Y, et al. Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms. Cancer Sci. 2011;102:1868-1873.
Satoh S, Tada H, Murakami M, et al. Circadian pharmacokinetics of mycophenolic acid and implication of genetic polymorphisms for early clinical events in renal transplant recipients. Transplantation. 2006;82:486-493.
Cecchin E, Innocenti F, D'Andrea M, et al. Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. J Clin Oncol. 2009;27:2457-2465.
van Schaik RH, van Agteren M, de Fijter JW, et al. UGT1A9 -275T>a/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients. Clin Pharmacol Ther. 2009;86:319-327.
Sánchez-Fructuoso AI, Maestro ML, Calvo N, et al. The prevalence of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T and its influence on mycophenolic acid pharmacokinetics in stable renal transplant patients. Transplant Proc. 2009;41:2313-2316.
Kuypers DR, Naesens M, Vermeire S, Vanrenterghem Y. The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin Pharmacol Ther. 2005;78:351-361.
Sandanaraj E, Jada SR, Shu X, et al. Influence of UGT1A9 intronic I399C>T polymorphism on SN-38 glucuronidation in Asian cancer patients. Pharmacogenomics J. 2008;8:174-185.
Lu Y, Fang Y, Wu X, Ma C, Wang Y, Xu L. Effects of UGT1A9 genetic polymorphisms on monohydroxylated derivative of oxcarbazepine concentrations and oxcarbazepine monotherapeutic efficacy in Chinese patients with epilepsy. Eur J Clin Pharmacol. 2017;73:307-315.
Frechen S. UGT DDI inhibition qualification. 2020 Accessed July 4, 2022. https://github.com/Open-Systems-Pharmacology/Qualification-DDI-UGT/releases/tag/v1.0
Kanacher T, Lindauer A, Mezzalana E, et al. A physiologically-based pharmacokinetic (PBPK) model network for the prediction of CYP1A2 and CYP2C19 drug-drug-gene interactions with fluvoxamine, omeprazole, S-mephenytoin, Moclobemide, Tizanidine, Mexiletine, Ethinylestradiol, and caffeine. Pharmaceutics. 2020;12:12.
University of Washington. DIDB-The Drug Interaction Database. 2022 Accessed December 8, 2022. https://www.druginteractionsolutions.org/
Centre UM. WHODrug Insight. Accessed July 4, 2022. https://insight.who-umc.org/
Trujillo ME, Arrington L, Patel Y, et al. Population pharmacokinetics of vericiguat in patients with heart failure with reduced ejection fraction: an integrated analysis. Clin Pharmacol Ther. 2022;112:1061-1069.